Canton Hathaway’s BioNTech BNTX Stock Holding History

Canton Hathaway’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-370	Closed	-$40K	–	243
2023 Q3	$40K	Buy	+370	New	+$40.9K	0.01%	168

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Canton Hathaway's BNTX Position: Q4 2023 in Review

Canton Hathaway sold out of BioNTech (BNTX) in Q4 2023, closing a stake of 370 shares — an estimated $40K sold.

Canton Hathaway first reported a position in BNTX in Q3 2023 and held it in 1 quarter. The position peaked at $40K in Q3 2023. 282 funds tracked by Wall St. Rank hold BNTX as of Q4 2023.

Canton Hathaway reported no remaining BioNTech position as of Q4 2023 after selling out during the quarter.
Canton Hathaway sold 370 BioNTech shares in Q4 2023, an estimated $40K.
Canton Hathaway first reported a position in BioNTech in Q3 2023 and held it in 1 quarter.
Canton Hathaway's BioNTech position peaked at $40K in Q3 2023.
282 funds tracked by Wall St. Rank held BioNTech as of Q4 2023.

Based on Canton Hathaway's 13F filing for Q4 2023, filed 30 Jan 2024.